COMPENDIUM ON FUNCTIONAL MEDICINE - Flipbook - Page 755
[46] Parthasarathy G, Chen J, Chen X, et al. Relationship between
microbiota of the colonic mucosa vs feces and symptoms, colonic
transit, and methane production in female patients with chronic
constipation. Gastroenterology. 2016;150(2):367-79.e1.
[47] Samuel BS, Hansen EE, Manchester JK, et al. Genomic and
metabolic adaptations of Methanobrevibacter smithii to the
human gut. Proc Natl Acad Sci USA. 2007;104(25):10643-8.
[48] Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency
is strongly associated with gut microbiota richness and
composition, enterotypes and bacterial growth rates. Gut.
2016;65(1):57-62.
[49] Kim G, Deepinder F, Morales W, et al. Methanobrevibacter
smithii is the predominant methanogen in patients with
constipation-predominant IBS and methane on breath. Dig Dis Sci.
2012;57(12):3213-8.
[50] Blachier F, Davila AM, Mimoun S, et al. Luminal sulfide and
large intestine mucosa: friend or foe? Amino Acids.
2010;39(2):335-47.
[51] Attene-Ramos MS, Wagner ED, Plewa MJ, et al. Evidence that
hydrogen sulfide is a genotoxic agent. Mol Cancer Res.
2006;4(1):9-14.
[52] Roediger WE, Moore J, Babidge W. Colonic sulfide in
pathogenesis and treatment of ulcerative colitis. Dig Dis Sci.
1997;42(8):1571-9.
[53] Ijssennagger N, van der Meer R, van Mil SWC. Sulfide as a
mucus barrier-breaker in inflammatory bowel disease? Trends Mol
Med. 2016;22(3):190-9.
[54] Suarez F, Furne J, Springfield J, et al. Insights into human
colonic physiology obtained from the study of flatus composition.
Am J Physiol Gastrointest Liver Physiol. 1997;272(5):G1028-33.
755
